Equities research analysts expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report sales of $44.63 million for the current quarter, Zacks reports. Five analysts have made estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from $35.00 million to $55.00 million. Arrowhead Pharmaceuticals reported sales of $650,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 6,766.2%. The firm is scheduled to report its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full year sales of $204.65 million for the current fiscal year, with estimates ranging from $179.56 million to $229.66 million. For the next financial year, analysts expect that the business will report sales of $76.22 million, with estimates ranging from $40.00 million to $129.00 million. Zacks’ sales averages are an average based on a survey of research analysts that follow Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, February 7th. The biotechnology company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.63). Arrowhead Pharmaceuticals had a negative net margin of 61.78% and a negative return on equity of 24.23%. The business had revenue of $34.66 million for the quarter, compared to the consensus estimate of $90.88 million.
ARWR stock traded up $0.21 during trading on Friday, reaching $18.13. 1,960,570 shares of the stock were exchanged, compared to its average volume of 1,828,788. Arrowhead Pharmaceuticals has a twelve month low of $5.35 and a twelve month high of $22.39. The company has a market cap of $1.69 billion, a P/E ratio of -27.89 and a beta of 2.23.
In related news, CEO Christopher Richard Anzalone sold 90,000 shares of the stock in a transaction that occurred on Wednesday, December 12th. The stock was sold at an average price of $14.07, for a total transaction of $1,266,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Douglas B. Given sold 3,000 shares of the stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $12.74, for a total value of $38,220.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 972,375 shares of company stock valued at $14,143,250. Company insiders own 4.80% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its position in shares of Arrowhead Pharmaceuticals by 339.8% during the second quarter. Bank of America Corp DE now owns 73,657 shares of the biotechnology company’s stock valued at $1,002,000 after acquiring an additional 56,909 shares during the last quarter. Bailard Inc. grew its holdings in Arrowhead Pharmaceuticals by 214.3% during the fourth quarter. Bailard Inc. now owns 110,000 shares of the biotechnology company’s stock valued at $1,366,000 after purchasing an additional 75,000 shares during the period. Northern Trust Corp grew its holdings in Arrowhead Pharmaceuticals by 380.1% during the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock valued at $14,464,000 after purchasing an additional 841,982 shares during the period. Candriam Luxembourg S.C.A. bought a new position in Arrowhead Pharmaceuticals during the third quarter valued at $9,853,000. Finally, Credit Suisse AG grew its holdings in Arrowhead Pharmaceuticals by 15.1% during the third quarter. Credit Suisse AG now owns 82,739 shares of the biotechnology company’s stock valued at $1,586,000 after purchasing an additional 10,843 shares during the period. 59.52% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Read More: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.